Signals from activation of B-cell receptor with anti-IgD can override the stimulatory effects of excess BAFF on mature B cells in vivo

Highlights • Signals from activated B-cell receptor (BCR) by anti-IgD could override the stimulatory effects of BAFF on mature B cells in vivo. • Treatment with excess BAFF increased spleen sizes, mature CD19+ B cells and serum IgM levels in vivo. • Co-treatment with anti-IgD significantly abrogated these stimulatory effects of BAFF. • Anti-IgD treatment reduced CD19, mIgD, mIgM and TACI expression on B cells. • Our results highlight the potential therapeutic utilities of an anti-IgD antibody.